Postmenopausal Tibolone Therapy: Biologic Principles and Applied Clinical Practice

Morris Notelovitz, MD, PhD, MB, BCh, FACOG, FRCOG

In This Article

Clinical Practice: Endometrial Surveillance

Tibolone therapy is associated with a slight but clinically insignificant increase in endometrial thickness when monitored by serial transvaginal ultrasound (TVUS) measurements over 1 year. Values for TVUS endometrial thickness in women treated with tibolone (2.5 mg daily) are similar to that following CCHT (2 mg E2 and 1mg NETA; CEE 0.625 mg and 2 mg MPA).

The TVUS endometrial thickness values in these studies peak at 1 year and do not change appreciably for the following 2 years of observation.[47] Some studies reported an association between tibolone usage and endometrial polyps (< 1%). The polyps were mostly inactive and benign.[47] Tibolone does not increase the growth of uterine myomas.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.